KLAR.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:29):

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy...

Stats
Dzisiejszy wolumen	245 729
Średni wolumen	323 610
Kapitalizacja rynkowa	35.04M
EPS	SEK-0.101 ( 2023-11-24 )
Następna data zysków	( SEK0 ) 2024-05-10
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.670
ATR14	SEK0.00900 (2.74%)

Wolumen Korelacja

Długi: -0.02 (neutral)

Krótki: -0.55 (weak negative)

Signal:(46.363) Neutral

Klaria Pharma Holding AB Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Klaria Pharma Holding AB Korelacja - Waluta/Towar

-0.71
( moderate negative )

-0.52
( weak negative )

0.00
( neutral )

-0.70
( moderate negative )

0.00
( neutral )

-0.21
( neutral )

Klaria Pharma Holding AB Finanse

Annual	2023
Przychody:	SEK0
Zysk brutto:	SEK-9 000.00 (0.00 %)
EPS:	SEK-0.360

FY	2023
Przychody:	SEK0
Zysk brutto:	SEK-9 000.00 (0.00 %)
EPS:	SEK-0.360

FY	2022
Przychody:	SEK5.87M
Zysk brutto:	SEK5.87M (100.00 %)
EPS:	SEK-1.100

FY	2021
Przychody:	SEK0.00
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-1.030

Financial Reports:

No articles found.

Klaria Pharma Holding AB

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.